M&A Activity
Organigram – Sanity Group Deal: What Changed and What it Means for Germany
This article was originally published in February 2026, and was most recently updated on September 22, 2026.
BAT
10stories
20 Septlast updated
More in BAT
- Adult-Use
Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest
LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total funding to date to over €100m.
- Press releases
Kanvas Receives Strategic Investment from Btomorrow Ventures, A Division Of BAT, As Lead Investor
THE Kanvas Co. (“Kanvas”), developer of patented electronic vaporizer technology solutions designed to deliver device safety, performance, and reliability for nicotine, cannabis, and cannabidiol (CBD) delivery systems, today announced the completion of a strategic investment (the ”Investment”).
- CBD Market
No longer up-in-smoke (only)
Earlier in the year, British American Tobacco (BAT), announced that they secured a nearly 20 percent interest in Canadian cannabis producer Organigram.
- Cannabis Daily News
PIVOT! PIVOT! PIVOT!
Some of Canada’s largest cannabis companies are losing market share after a tough year, according to data analyzed by ATB Capital Markets.
- Adult-Use
Markets: PepsiCo Launches German Hemp Drink, Curaleaf’s $130m Backer, Organigram, Canopy Growth, Fyllo et al…
FOLLOWING its recent purchase of UK cannabis firm EMMAC Life Sciences, Curaleaf has now secured an additional $130m from a single institutional investor to fund its European ambitions.
- CBD Market
Why Big Tobacco is all in on $OGI
After Moncton-based Organigram announced a subsidiary of British American Tobacco (BAT) was taking a 19.9% stake in the company for $220 million, CEO Greg Engel shared what he believes the deal means for the company.
